We canāt show the full text here under this license. Use the link below to read it at the source.
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
Greater weight loss with once-weekly semaglutide compared to other similar drugs, regardless of stomach side effects
AI simplified
Abstract
Nausea and vomiting contributed minimally (<0.1 kg) to weight loss with semaglutide compared to other at the end of treatment.
- Weight loss from baseline to end of treatment was 3.78 kg in SUSTAIN 3, 2.26 kg in SUSTAIN 7, and 3.82 kg in SUSTAIN 10.
- In SUSTAIN 3, nausea/vomiting mediated a weight loss difference of 0.05 kg by week 12 and 0.09 kg at the end of treatment.
- In SUSTAIN 7, the mediated weight loss difference was 0.06 kg by week 12 and 0.03 kg at the end of treatment for low-dose comparison, and 0.08 kg by week 12 and 0.04 kg at the end of treatment for high-dose comparison.
- In SUSTAIN 10, nausea/vomiting mediated a weight loss difference of 0.05 kg by week 12 and 0.09 kg at the end of treatment.
- Overall, nausea/vomiting contributed minimally to the greater weight loss achieved with semaglutide compared to other GLP-1 receptor agonists.
AI simplified
Key numbers
3.78 kg
Weight Loss with Semaglutide vs. Exenatide ER
Weight loss at end of treatment in SUSTAIN 3
0.05 kg
Nausea/Vomiting Mediated Weight Loss
Mediated weight loss from baseline to end of treatment in SUSTAIN 3
3.55 kg
Weight Loss with Semaglutide 1.0 mg in SUSTAIN 7
Total weight loss at end of treatment